Vivo Capital, LLC — 13F Holdings & Portfolio
CIK 1674712 · latest 13F-HR filed 2026-11-13
Vivo Capital, LLC manages $908.7M in 13F-reported U.S. long-equity assets across 50 reported positions as of its 2026-09-30 13F-HR filing. Its largest disclosed positions are PRAX (8.69%), TRVI (6.67%), ERAS (6.49%). Quarter over quarter (versus its 2026-06-30 filing) the fund opened 8 new positions and exited 5; 13 existing positions rose in reported value and 27 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-11-13
vs 2026-06-30
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
Portfolio map
Q3 26Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.
Sector mix
% of 13F valueSectors from each company's SIC code; funds and ETFs grouped separately.
Biggest buys and sells
Q2 26 → Q3 26Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.
13F assets and positions
5 quartersTotal reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.
Top positions over time
reported valueThe eight largest current positions, valued at each quarter end.
Concentration
top 10 = 51.3%Cumulative share of the portfolio held in the largest N positions.
As of the firm’s regulatory filing dated Mar 31, 2026.
PALO ALTO, CA 94301
| Name | Title / Status | Ownership | Type |
|---|---|---|---|
| AGGARWAL, GAURAV Control | MANAGING PARTNER since Apr 2024 | 5–10% | Individual |
| CHANG, MICHAEL, J. Control | MANAGING PARTNER since Jan 2021 | 5–10% | Individual |
| ENGLEMAN, EDGAR, GEORGE Control | MANAGING PARTNER since Jun 2005 | 10–25% | Individual |
| FU, SHAN, (NMN) Control | MANAGING PARTNER since Jan 2015 | 10–25% | Individual |
| KUNG, FRANK, FANG-CHIEN Control | MANAGING PARTNER since Jun 2005 | 25–50% | Individual |
| SHEU, CINTHIA, HUI-HSIN Control | PARTNER / CHIEF OPERATING OFFICER since Apr 2008 | Less than 5% | Individual |
| WU, ZHANPING, (NMN) Control | PARTNER / GENERAL COUNSEL / CHIEF COMPLIANCE OFFICER since Nov 2019 | Less than 5% | Individual |
Ownership & leadership changes · 11 filings with changes since Mar 28, 2012
From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.
- No longer listedNIELSEN, JACK, BECH · MANAGING PARTNER · 5–10% · control person · listed since Jan 2021
- AddedAGGARWAL, GAURAV · MANAGING PARTNER · 5–10% · control person
- No longer listedLU, HONGBO, (NMN) · MANAGING PARTNER · 10–25% · control person · listed since Jan 2021
- AddedCHANG, MICHAEL, J. · MANAGING PARTNER · 5–10% · control person
- AddedLU, HONGBO, (NMN) · MANAGING PARTNER · 10–25% · control person
- AddedNIELSEN, JACK, BECH · MANAGING PARTNER · 5–10% · control person
- ChangedENGLEMAN, EDGAR, GEORGE · ownership 25–50% → 10–25%
- ChangedFU, SHAN, (NMN) · ownership 25–50% → 10–25%
- ChangedSHEU, CINTHIA, HUI-HSIN · title CHIEF OPERATING OFFICER → PARTNER / CHIEF OPERATING OFFICER
- ChangedWU, ZHANPING, (NMN) · title GENERAL COUNSEL / CHIEF COMPLIANCE OFFICER → PARTNER / GENERAL COUNSEL / CHIEF COMPLIANCE OFFICER
- No longer listedCHA, ALBERT, (NMN) · MANAGING PARTNER · 10–25% · control person · listed since Jun 2005
- ChangedENGLEMAN, EDGAR, GEORGE · ownership 10–25% → 25–50%
- ChangedFU, SHAN, (NMN) · ownership 10–25% → 25–50%
- No longer listedYU, CHEN, MING · MANAGING PARTNER · 10–25% · control person · listed since Jan 2015
- AddedWU, ZHANPING, (NMN) · GENERAL COUNSEL / CHIEF COMPLIANCE OFFICER · Less than 5% · control person
- ChangedCHA, ALBERT, (NMN) · title MANAGING MEMBER → MANAGING PARTNER
- ChangedENGLEMAN, EDGAR, GEORGE · title MANAGING MEMBER → MANAGING PARTNER
- ChangedKUNG, FRANK, FANG-CHIEN · title MANAGING MEMBER → MANAGING PARTNER
- ChangedSHEU, CINTHIA, HUI-HSIN · title CHIEF COMPLIANCE OFFICER AND CHIEF OPERATING OFFICER → CHIEF OPERATING OFFICER
- ChangedCHA, ALBERT, (NMN) · ownership 25–50% → 10–25%
- ChangedENGLEMAN, EDGAR, GEORGE · ownership 25–50% → 10–25%
- ChangedFU, SHAN, (NMN) · ownership 5–10% → 10–25%
- ChangedSHEU, CINTHIA, HUI-HSIN · title CHIEF COMPLIANCE OFFICER AND VP OF FINANCE → CHIEF COMPLIANCE OFFICER AND CHIEF OPERATING OFFICER
- AddedFU, SHAN, (NMN) · MANAGING PARTNER · 5–10% · control person
- AddedYU, CHEN, MING · MANAGING PARTNER · 10–25% · control person
Older changes (2 more filings)
- ChangedSHEU, CINTHIA, HUI-HSIN · title VP FINANCE → CHIEF COMPLIANCE OFFICER AND VP OF FINANCE; now a control person
- ListedCHA, ALBERT, (NMN) · MANAGING MEMBER · 25–50% · control person
- ListedENGLEMAN, EDGAR, GEORGE · MANAGING MEMBER · 25–50% · control person
- ListedKUNG, FRANK, FANG-CHIEN · MANAGING MEMBER · 25–50% · control person
- ListedSHEU, CINTHIA, HUI-HSIN · VP FINANCE · Less than 5%
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Adds (vs prior quarter)
- Faeth Therapeutics Inc$7.1M +39.2%
- LB Pharmaceuticals Inc$4.7M +18.3%
- Achieve Life Science Inc$4.3M +23.9%
- CAMP4 Therapeutics Corporation$4.0M +21.6%
- Eupraxia Pharmaceuticals Inc$3.4M +37.7%
Top Trims
- Trevi Therapeutics Inc-$34.4M -36.3%
- Tenax Therapeutics Inc-$31.6M -87.0%
- Dyne Therapeutics Inc-$26.3M -76.0%
- Bright Minds Biosciences Inc-$18.3M -46.8%
- Erasca Inc-$16.7M -22.0%
New Positions
- Entera Bio Ltd$35.7M
- Korsana Biosciences Inc$28.1M
- Blossomhill Therapeutics Inc$27.8M
- Vor Biopharma Inc$10.5M
- Cue Biopharma Inc$7.2M
Exited Positions
- Sinovac Biotech Ltd.$38.2M
- Dianthus Therapeutics Inc$34.5M
- Geron Corp$11.1M
- ALX Oncology Holdings Inc$6.6M
- Unicycive Therapeutics$2.6M
Vivo Capital, LLC Holdings (2026-09-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | Praxis Precision Medicines | PRAX | 74006W207 | $79.0M | 8.69% | 271,116 | SH |
| 2 | Trevi Therapeutics Inc | TRVI | 89532M101 | $60.6M | 6.67% | 4,229,683 | SH |
| 3 | Erasca Inc | ERAS | 29479A108 | $58.9M | 6.49% | 4,020,619 | SH |
| 4 | Arrivent BioPharma Inc | AVBP | 04272N102 | $54.1M | 5.95% | 1,787,104 | SH |
| 5 | Abivax SA | ABVX | 00370M103 | $41.1M | 4.52% | 414,899 | SH |
| 6 | Entera Bio Ltd | ENTX | M40527109 | $35.7M | 3.92% | 12,254,901 | SH |
| 7 | Aclaris Therapeutics Inc | ACRS | 00461U105 | $35.2M | 3.88% | 6,694,637 | SH |
| 8 | Alto Neuroscience Inc | ANRO | 02157Q109 | $34.7M | 3.82% | 1,359,915 | SH |
| 9 | Tango Therapeutics Inc | TNGX | 87583X109 | $34.4M | 3.79% | 1,379,769 | SH |
| 10 | Corvus Pharmaceuticals Inc | CRVS | 221015100 | $32.3M | 3.56% | 2,805,816 | SH |
| 11 | LB Pharmaceuticals Inc | LBRX | 50180M108 | $30.7M | 3.38% | 800,000 | SH |
| 12 | Korsana Biosciences Inc | KRSA | 23255M303 | $28.1M | 3.09% | 877,020 | SH |
| 13 | Blossomhill Therapeutics Inc | BLSM | 095130100 | $27.8M | 3.06% | 1,493,740 | SH |
| 14 | Faeth Therapeutics Inc | FTH | 81728A207 | $25.1M | 2.76% | 844,576 | SH |
| 15 | CAMP4 Therapeutics Corporation | CAMP | 13463J101 | $22.6M | 2.48% | 5,584,111 | SH |
| 16 | Achieve Life Science Inc | QUIT | 004468500 | $22.3M | 2.45% | 2,751,032 | SH |
| 17 | SAB Biotherapeutics Inc | SABS | 78397T202 | $21.9M | 2.41% | 6,915,011 | SH |
| 18 | DBV Technologies SA | DBVT | 23306J309 | $21.7M | 2.39% | 1,844,758 | SH |
| 19 | Bright Minds Biosciences Inc | DRUG | 10919W405 | $20.8M | 2.29% | 417,879 | SH |
| 20 | Design Therapeutics Inc | DSGN | 25056L103 | $20.3M | 2.23% | 1,612,903 | SH |
| 21 | AN2 Therapeutics Inc | ANTX | 037326105 | $16.8M | 1.85% | 3,153,640 | SH |
| 22 | Moonlake Immunotherapeutics | MLTX | 61559X104 | $16.4M | 1.80% | 1,400,000 | SH |
| 23 | Minerva Neurosciences Inc | NERV | 603380205 | $14.5M | 1.59% | 4,322,747 | SH |
| 24 | Odyssey Therapeutics Inc | ODTX | 67613T104 | $12.8M | 1.41% | 575,000 | SH |
| 25 | Oric Pharmaceuticals Inc | ORIC | 68622P109 | $12.5M | 1.37% | 924,392 | SH |
| 26 | Eupraxia Pharmaceuticals Inc | EPRX | 29842P105 | $12.3M | 1.35% | 1,350,000 | SH |
| 27 | Vor Biopharma Inc | VOR | 929033207 | $10.5M | 1.16% | 550,358 | SH |
| 28 | Editas Medicine Inc | EDIT | 28106W103 | $9.1M | 1.01% | 3,555,250 | SH |
| 29 | Surrozen Inc | SRZN | 86889P208 | $8.4M | 0.92% | 260,000 | SH |
| 30 | Dyne Therapeutics Inc | DYN | 26818M108 | $8.3M | 0.91% | 514,402 | SH |
| 31 | Aura Biosciences Inc | AURA | 05153U107 | $7.3M | 0.81% | 1,166,667 | SH |
| 32 | Cue Biopharma Inc | CUE | 22978P205 | $7.2M | 0.80% | 280,057 | SH |
| 33 | Monopar Therapeutics Inc | MNPR | 61023L207 | $7.2M | 0.79% | 90,500 | SH |
| 34 | Satellos Bioscience Inc | MSLE | 80401L803 | $6.9M | 0.76% | 813,666 | SH |
| 35 | Olema Pharmaceuticals Inc | OLMA | 68062P106 | $5.8M | 0.64% | 671,843 | SH |
| 36 | Pepgen Inc | PEPG | 713317105 | $5.6M | 0.62% | 2,325,000 | SH |
| 37 | Onkure Therapeutics Inc | OKUR | 68277Q105 | $5.3M | 0.58% | 1,927,710 | SH |
| 38 | Attovia Therapeutics Inc | ATTO | 04987L102 | $5.1M | 0.57% | 300,000 | SH |
| 39 | ADARx Pharmaceuticals Inc | ADRX | 00654F105 | $5.1M | 0.56% | 255,158 | SH |
| 40 | Tenax Therapeutics Inc | TENX | 88032L605 | $4.7M | 0.52% | 2,500,000 | SH |
| 41 | Valneva SE | VALN | 92025Y103 | $4.7M | 0.52% | 763,199 | SH |
| 42 | Avalo Therapeutics Inc | AVTX | 05338F306 | $4.2M | 0.46% | 275,000 | SH |
| 43 | Compass Therapeutics Inc | CMPX | 20454B104 | $3.6M | 0.39% | 3,423,547 | SH |
| 44 | Sera Prognostics Inc | SERA | 81749D107 | $3.4M | 0.38% | 1,650,440 | SH |
| 45 | Instil Bio Inc | TIL | 45783C200 | $2.1M | 0.23% | 292,743 | SH |
| 46 | InMed Pharmaceuticals Inc | INM | 457637700 | $1.1M | 0.12% | 824,874 | SH |
| 47 | Bolt Biotherapeutics Inc | BOLT | 097702203 | $266.5K | 0.03% | 72,414 | SH |
| 48 | Pasithea Therapeutics Corp | KTTA | 70261F202 | $183.8K | 0.02% | 372,796 | SH |
| 49 | Precision Biosciences Inc | DTIL | 74019P207 | $29.3K | 0.00% | 4,675 | SH |
| 50 | Jasper Therapeutics Inc | JSPR | 471871202 | $3.7K | 0.00% | 5,364 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-09-30 | 2026-11-13 | $908.7M | 50 | 0001213900-26-119459 |
| 2026-06-30 | 2026-08-14 | $1.10B | 47 | 0001213900-26-089935 |
| 2026-03-31 | 2026-05-15 | $1.20B | 45 | 0001213900-26-057929 |
| 2026-03-31 | 2026-05-20 | $1.20B | 46 | 0001213900-26-059247 |
| 2025-12-31 | 2026-02-13 | $1.55B | 47 | 0001213900-26-016236 |
| 2025-09-30 | 2025-11-14 | $1.24B | 47 | 0001213900-25-110767 |
PALO ALTO, CA 94301